Skip to main
PTGX
PTGX logo

Protagonist Therapeutics (PTGX) Stock Forecast & Price Target

Protagonist Therapeutics (PTGX) Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 42%
Buy 53%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Protagonist Therapeutics Inc's stock outlook is bolstered by an increased EV/Sales multiple to 9.5x, reflecting the company's significant growth potential driven by upcoming milestone payments and royalties, which are expected to yield high margins. The company's pipeline products, particularly icotrokinra, demonstrate promising efficacy enhancements projected to capture substantial market share in conditions like ulcerative colitis (UC) and psoriasis (PsO), with peak unadjusted revenues estimated to reach $3.2 billion and $3 billion, respectively. Additionally, the potential success of preclinical programs in obesity and hepcidin-related treatments could further enhance investor sentiment and contribute to share price appreciation.

Bears say

Protagonist Therapeutics Inc. faces significant regulatory risks that could potentially delay or prevent the approval of its pipeline assets, adversely affecting future cash flows and share price. The company continues to incur net losses, suggesting a reliance on additional capital raises to complete drug development, which may dilute shareholder value. Furthermore, the company may encounter challenges in clinical trial recruitment and potential serious side effects of its product candidates, further complicating their market entry and acceptance.

Protagonist Therapeutics (PTGX) has been analyzed by 19 analysts, with a consensus rating of Buy. 42% of analysts recommend a Strong Buy, 53% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Protagonist Therapeutics (PTGX) Forecast

Analysts have given Protagonist Therapeutics (PTGX) a Buy based on their latest research and market trends.

According to 19 analysts, Protagonist Therapeutics (PTGX) has a Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $48.26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $48.26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Protagonist Therapeutics (PTGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.